Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
2024 · Clinical Breast Cancer · 5 citations
https://doi.org/10.1016/j.clbc.2024.05.004
İ
İrem Öner
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
45
Papers
105
Citations
5
h-index
3
i10-index
İrem Öner is an academic researcher. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 5, co-authored 39 publications.
ORCID: 0000-0001-9486-6187Papers by this author
worksRelationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study
2024 · International Journal of Clinical Oncology · 4 citations
https://doi.org/10.1007/s10147-024-02528-w
Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy
2024 · BMC Cancer · 3 citations
https://doi.org/10.1186/s12885-024-13100-0
A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
2025 · Medicina · 1 citations
https://doi.org/10.3390/medicina61020360
Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer
2024 · Future Oncology · 0 citations
https://doi.org/10.1080/14796694.2024.2432850
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat